FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Neil Senzer

Research Profile

Disorders

Procedures

Living Beings

Adenoviridae

Chemicals & Drugs

Concepts & Ideas

Phenomena

RNA Interference

Co-author Network

Publications

TOP 3
Neil Senzer; Minal Barve; Cynthia Bedell; Gerald Edelman; Derek Nemunaitis; John Nemunaitis; Robert Nunan; Kathleen F Pirollo; Antonina Rait; Esther H Chang
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors.
Donald D Rao; Neil Senzer; Zhaohui Wang; John Nemunaitis
RNA interference and personalized cancer therapy.
Donald D Rao; Neil Senzer; Zhaohui Wang; Chris M Jay; Padmasini Kumar; John Nemunaitis
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Neil Senzer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Neil Senzer; Minal Barve; Cynthia Bedell; Gerald Edelman; Derek Nemunaitis; John Nemunaitis; Robert Nunan; Kathleen F Pirollo; Antonina Rait; Esther H Chang
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy 2013;21(5):1096-103.
2013: Donald D Rao; Neil Senzer; Zhaohui Wang; John Nemunaitis
RNA interference and personalized cancer therapy.
Discovery medicine 2013;15(81):101-10.
2013: Donald D Rao; Neil Senzer; Zhaohui Wang; Chris M Jay; Padmasini Kumar; John Nemunaitis
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.
Methods in molecular biology (Clifton, N.J.) 2013;942():259-78.
2012: Andrew J Wagner; Feng Chai; Edwin Choy; Ian Davis; Steven G Dubois; James Geller; John M Goldberg; David Hogg; Ian Judson; Alberto Pappo; Lee Rosen; Brian Schwartz; Neil Senzer; Carol Waghorne; George D Demetri
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Cancer 2012;118(23):5894-902.
2012: Alex W Tong; Vincenzo Cerullo; Akseli Hemminki; Neil Senzer; Nancy Smyth Templeton; John Nemunaitis
Oncolytic viruses for induction of anti-tumor immunity.
Current pharmaceutical biotechnology 2012;13(9):1750-60.
2012: Kenneth J Chang; Nadar N Hanna; Harlan Pinto; Tony Reid; Neil Senzer; Amitabh Chak; Stephen Swisher; Roy Soetikno
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Gastrointestinal endoscopy 2012;75(6):1139-46.e2.
2012: Neil Senzer; David M Shanahan; Nicolas Taquet; Gladice Wallraven; Zhaohui Wang; Yang Yu; Fabienne Norvell; Jonathan Oh; Beena O Pappen; Connor Phalon; Donald D Rao; Minal Barve; Cynthia Bedell; Peter Beitsch; F Charles Brunicardi; Candice Higgs; Chris M Jay; J Kuhn; Padmasini Kumar; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Phillip B Maples; Anton Melnyk; Susan W Mill; John Nemunaitis
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(3):679-86.
2012: J Randolph Hecht; Milind Javle; Milan Kovacevic; John Nemunaitis; Mitchell Posner; Anthony Reid; Alexander Rosemurgy; Neil Senzer; Gretta Blatner; Marcia Canto; Amitabh Chak; Kenneth J Chang; Theodore Chung; Richard Erickson; James Farrell; Nadar N Hanna; Irving Waxman; Mark Thornton
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
Gastrointestinal endoscopy 2012;75(2):332-8.
2012: Shi-He Liu; John Nemunaitis; Michael Norman; Bert O'Malley; Donald D Rao; Robbi Sanchez; Neil Senzer; Nancy S Templeton; Zhaohui Wang; Guisheng Zhou; David Dawson; Francesco J DeMayo; William E Fisher; Richard Gibbs; Marie-Claude Gingras; F Charles Brunicardi
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.
PloS one 2012;7(8):e40452.
2012: Nancy Smyth Templeton; Neil Senzer
Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.
Journal of drug delivery 2012;2012():173465.
2012: Olivia Simmons; Neil Senzer; Phillip B Maples; John Nemunaitis
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.
ISRN oncology 2012;2012():247657.
2011: Zhaohui Wang; Donald D Rao; Neil Senzer; John Nemunaitis
RNA interference and cancer therapy.
Pharmaceutical research 2011;28(12):2983-95.
2011: Gregory Nemunaitis; Beena O Pappen; Anagha P Phadke; Neil Senzer; Nancy S Templeton; Alex W Tong; Tal Yardeni; Henry Allen; Cynthia Bedell; William A Gahl; Cathy Hernandez; Marjan Huizing; Chris M Jay; J Kuhn; Phillip B Maples; John Nemunaitis
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.
Human gene therapy 2011;22(11):1331-41.
2011: Anagha P Phadke; Donald D Rao; Stephanie Scott; Neil Senzer; Nancy S Templeton; Zhaohui Wang; Craig Webb; Francis Charles Brunicardi; Salina Chen; Egeenee Q Daniels; Dawna Dylewski; Hermann B Frieboes; Courtney Haddock; Chris M Jay; Padmasini Kumar; Shengnan Liu; Phillip B Maples; David Monsma; John Nemunaitis; Beena O Pappen; Alex W Tong
In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.
DNA and cell biology 2011;30(9):715-26.
2011: John Nemunaitis; Neil Senzer; Barry Cooper; Michael Nemunaitis; Cynthia Bedell; jack w singer; Fred B Oldham
Procoagulant inhibitory properties of paclitaxel poliglumex.
International journal of general medicine 2011;4():5-11.
2011: Jairo Olivares; Padmasini Kumar; Yang Yu; Phillip B Maples; Neil Senzer; Cynthia Bedell; Minal Barve; Alex Tong; Beena O Pappen; Joseph Kuhn; Mitchell Magee; Gladice Wallraven; John Nemunaitis
Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(1):183-92.
2010: D D Rao; P B Maples; Neil Senzer; P Kumar; Z Wang; B O Pappen; Y Yu; C Haddock; C Jay; A P Phadke; S Chen; J Kuhn; D Dylewski; S Scott; D Monsma; Craig Webb; A Tong; D Shanahan; John Nemunaitis
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.
Cancer gene therapy 2010;17(11):780-91.
2010: Gregory Nemunaitis; Phillip B Maples; Chris Jay; William A Gahl; Marjan Huizing; Justin Poling; Alex W Tong; Anagha P Phadke; Beena O Pappen; Cynthia Bedell; Nancy S Templeton; Joseph Kuhn; Neil Senzer; John Nemunaitis
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy.
The journal of gene medicine 2010;12(5):403-12.
2010: John Nemunaitis; Alex W Tong; Michael Nemunaitis; Neil Senzer; Anagha P Phadke; Cynthia Bedell; Ned Adams; Yu-An Zhang; Phillip B Maples; Salina Chen; Beena Pappen; James Burke; Daiju Ichimaru; Yasuo Urata; Toshiyoshi Fujiwara
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(2):429-34.
2009: Neil Senzer; Howard Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5763-71.
2009: R M Eager; C C Cunningham; Neil Senzer; D A Richards; R N Raju; B Jones; M Uprichard; John Nemunaitis
Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2009;21(6):464-72.
2009: John Nemunaitis; M Nemunaitis; Neil Senzer; P Snitz; C Bedell; Padmasini Kumar; Beena Pappen; P B Maples; D Shawler; H Fakhrai
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.
Cancer gene therapy 2009;16(8):620-4.
2009: Donald D Rao; John S Vorhies; Neil Senzer; John Nemunaitis
siRNA vs. shRNA: similarities and differences.
Advanced drug delivery reviews 2009;61(9):746-59.
2009: Alex W Tong; Chris M Jay; Neil Senzer; Phillip B Maples; John Nemunaitis
Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.
Current gene therapy 2009;9(1):45-60.
2009: Neil Senzer; John Nemunaitis
A review of contusugene ladenovec (Advexin) p53 therapy.
Current opinion in molecular therapeutics 2009;11(1):54-61.
2009: C Mees; John Nemunaitis; Neil Senzer
Transcription factors: their potential as targets for an individualized therapeutic approach to cancer.
Cancer gene therapy 2009;16(2):103-12.
2009: Neil Senzer; Donald Rao; John Nemunaitis
Letter to the editor: Does dicer expression affect shRNA processing?
Gene regulation and systems biology 2009;3():103-4.
2009: Anagha P Phadke; Chris Jay; Salina J Chen; Courtney Haddock; Zhaohui Wang; Yang Yu; Derek Nemunaitis; Gregory Nemunaitis; Nancy S Templeton; Neil Senzer; Phillip B Maples; Alex W Tong; John Nemunaitis
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2.
Gene regulation and systems biology 2009;3():89-101.
2009: Robert M Eager; C Casey Cunningham; Neil Senzer; Joe Stephenson; Stephen P Anthony; Steven J O'Day; Gary Frenette; Anna C Pavlick; Barry Jones; Margaret Uprichard; John Nemunaitis
Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma.
BMC cancer 2009;9():263.
2008: Minal Barve; James Bender; Neil Senzer; Casey Cunningham; F Anthony Greco; David McCune; Ronald Steis; Hung Khong; Donald Richards; Joe Stephenson; Prasanthi Ganesa; John Nemunaitis; Glenn Ishioka; Beena Pappen; Michael Nemunaitis; Michael Morse; Bonnie Mills; Phillip B Maples; Jeffrey Sherman; John J Nemunaitis
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(27):4418-25.
2008: Shushan Rana; Phillip B Maples; Neil Senzer; John Nemunaitis
Stathmin 1: a novel therapeutic target for anticancer activity.
Expert review of anticancer therapy 2008;8(9):1461-70.
2008: Chris Jay; Gregory Nemunaitis; John Nemunaitis; Neil Senzer; Stephan Hinderlich; Daniel Darvish; Julie Ogden; John Eager; Alex Tong; Phillip B Maples
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).
Gene regulation and systems biology 2008;2():243-52.
2007: John Nemunaitis; Neil Senzer; S Sarmiento; Yu-An Zhang; R Arzaga; B Sands; Phillip B Maples; Alex W Tong
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients.
Cancer gene therapy 2007;14(11):885-93.
2007: Paul B Fisher; Devanand Sarkar; Irina Lebedeva; Luni Emdad; Pankaj Gupta; Moira Sauane; Zao-Zhong Su; Steven Grant; Paul Dent; David T Curiel; Neil Senzer; John Nemunaitis
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma.
Toxicology and applied pharmacology 2007;224(3):300-7.
2007: John Nemunaitis; Neil Senzer; I Khalil; Yuqiao Shen; Padmasini Kumar; Alex Tong; J Kuhn; J Lamont; M Nemunaitis; D Rao; Yu-An Zhang; Y Zhou; John S Vorhies; Phillip B Maples; C Hill; D Shanahan
Proof concept for clinical justification of network mapping for personalized cancer therapeutics.
Cancer gene therapy 2007;14(8):686-95.
2007: John Nemunaitis; John S Vorhies; Beena Pappen; Neil Senzer
10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients.
Cancer gene therapy 2007;14(8):762-3.
2007: Neil Senzer; John Nemunaitis; Michael Nemunaitis; Jeffrey Lamont; Martin Gore; Hani Gabra; Rosalind Eeles; Nayanta Sodha; Frank J Lynch; Louis A Zumstein; Kerstin B Menander; Robert E Sobol; Sunil Chada
p53 therapy in a patient with Li-Fraumeni syndrome.
Molecular cancer therapeutics 2007;6(5):1478-82.
2006: John Nemunaitis; Robert O Dillman; Paul Schwarzenberger; Neil Senzer; Casey Cunningham; Jodi Cutler; Alex Tong; Padmasini Kumar; Beena Pappen; Cody Hamilton; Edward DeVol; Phillip B Maples; Lily Liu; Terry Chamberlin; Daniel L Shawler; Habib Fakhrai
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(29):4721-30.
2006: John Nemunaitis; Svetislava Vukelja; Donald Richards; Casey Cunningham; Neil Senzer; John Nugent; Houston Duncan; Barry Jones; Eric Haltom; Margaret J Uprichard
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
Cancer investigation 2006;24(6):553-61.
2006: John Nemunaitis; Thomas Meyers; Neil Senzer; Casey Cunningham; Howard West; Eric Vallieres; Stephen P Anthony; Svetislava Vukelja; Barry Berman; Heather Tully; Beena Pappen; Stephen Sarmiento; Rosemarie Arzaga; Steven Duniho; Susan Engardt; Madeleine Meagher; Martin A Cheever
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(6):1185-91.
2006: John H Suh; Baldassarre Stea; Abdenour Nabid; John J Kresl; André Fortin; Jean-Philippe Mercier; Neil Senzer; Eric L Chang; Adam P Boyd; Pablo J Cagnoni; Edward Shaw
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):106-14.
2006: James Mezhir; Kerrington D Smith; Mitchell C Posner; Neil Senzer; Bakhtiar Yamini; Donald Kufe; Ralph R Weichselbaum
Ionizing radiation: a genetic switch for cancer therapy.
Cancer gene therapy 2006;13(1):1-6.
2005: Neil Senzer; Yuqiao Shen; Colin Hill; John Nemunaitis
Individualised cancer therapeutics: dream or reality?
Expert opinion on therapeutic targets 2005;9(6):1189-201.
2005: Yuqiao Shen; Neil Senzer; John Nemunaitis
Individualised cancer therapeutics: dream or reality? Therapeutics construction.
Expert opinion on biological therapy 2005;5(11):1427-41.
2005: James Mezhir; Hank Schmidt; Bakhtiar Yamini; Neil Senzer; Mitchell C Posner; Donald Kufe; Ralph R Weichselbaum
Chemo-inducible gene therapy.
Anti-cancer drugs 2005;16(10):1053-8.
2005: James M. McLoughlin; Todd M McCarty; Casey Cunningham; Valerie Clark; Neil Senzer; John Nemunaitis; Joseph A Kuhn
TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
Annals of surgical oncology 2005;12(10):825-30.
2005: John Nemunaitis; Irene A Eiseman; Casey Cunningham; Neil Senzer; Adrienne Williams; Peter F Lenehan; Stephen C Olson; Paul Bycott; Michael Schlicht; Rebecca Zentgraff; Dong M Shin; Ralph G Zinner
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3846-53.
2005: Neil Senzer; James Arsenau; Donald Richards; Barry Berman; John R MacDonald; Sheri Smith
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
American journal of clinical oncology 2005;28(1):36-42.
2005: John Nemunaitis; Casey Cunningham; Neil Senzer; Megan Gray; Fred Oldham; John Pippen; Robert G Mennel; Amy Eisenfeld
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
Cancer investigation 2005;23(8):671-6.
2005: John Nemunaitis; Ned Adams; Casey Cunningham; Neil Senzer; Sue Graham; David Barrera; John Nugent; Clinton Stewart
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
The Journal of oncology management : the official journal of the American College of Oncology Administrators 2005;14(3):77-90.
2005: Alex W Tong; John Nemunaitis; Dan Su; Yuan Zhang; Casey Cunningham; Neil Senzer; GEORGES NETTO; Dawn Rich; Abner M Mhashilkar; Karen Parker; Keith Coffee; Rajagopal Ramesh; Suhendan Ekmekcioglu; Elizabeth A Grimm; Jill van Wart Hood; James Merritt; Sunil Chada
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(1):160-72.
2005: C Casey Cunningham; Sunil Chada; James A Merritt; Alex Tong; Neil Senzer; Yuan Zhang; Abner M Mhashilkar; Karen Parker; Svetislava Vukelja; Don Richards; Jill Hood; Keith Coffee; John Nemunaitis
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(1):149-59.
2004: Wells A Messersmith; Daniel Laheru; Neil Senzer; Ross C Donehower; Paula Grouleff; Theresa Rogers; Sean K Kelley; David A Ramies; Bert L Lum; Manuel Hidalgo
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6522-7.
2004: Arno J Mundt; Srinivasan Vijayakumar; John Nemunaitis; Alan B Sandler; Herbert Schwartz; Nadar N Hanna; Terrance D Peabody; Neil Senzer; Karen Chu; Camilla S Rasmussen; Paul D Kessler; Henrik S Rasmussen; Michael A Warso; Donald Kufe; Tapas Das Gupta; Ralph R Weichselbaum
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5747-53.
2004: Neil Senzer; Sridhar Mani; Alexander Rosemurgy; John Nemunaitis; Casey Cunningham; Chandan Guha; Natalia Bayol; Michelle Gillen; Karen Chu; Camilla Rasmussen; Henrik Rasmussen; Donald Kufe; Ralph Weichselbaum; Nadar N Hanna
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(4):592-601.
2004: Denis Soulieres; Neil Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):77-85.
2003: Timothy Dziuk; Neil Senzer
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
Seminars in oncology 2003;30(6 Suppl 18):49-57.
2003: John Nemunaitis; Casey Cunningham; Neil Senzer; Joseph Kuhn; Jennifer Cramm; Craig Litz; Robert Cavagnolo; Ann Cahill; Caroline Clairmont; Mario Sznol
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Cancer gene therapy 2003;10(10):737-44.
2003: John Nemunaitis; Casey Cunningham; Neil Senzer
Enhanced oncolytic potency of replicative adenovirus expressing p53.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(1):5-7.
2002: Neil Senzer
Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation.
Seminars in oncology 2002;29(6 Suppl 19):47-52.
2002: Neil Senzer
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Seminars in oncology 2002;29(6 Suppl 19):38-41.
2002: L Chinsoo Cho; Neil Senzer; George N Peters
Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers.
American journal of surgery 2002;183(6):650-4.
2002: Matthew A Arquette; Todd Wasserman; Ramaswamy Govindan; David Garfield; Neil Senzer; Heidi Gillenwater; Mark A Socinski
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
Seminars in radiation oncology 2002;12(1 Suppl 1):59-61.
1997: Joanne L Blum; Stephen E Jones; J W Fay; Neil Senzer; Robert G Mennel
Guidelines for systemic therapy of early stage breast cancer.
Breast cancer research and treatment 1997;43(3):259-76.